Jupiter Neurosciences Files 8-K

Ticker: JUNS · Form: 8-K · Filed: 2025-07-10T00:00:00.000Z

Sentiment: neutral

Topics: 8-K, regulatory-filing

TL;DR

JUPITER NEUROSCIENCES FILED AN 8-K, DETAILS UNCLEAR FROM THIS SNIPPET.

AI Summary

Jupiter Neurosciences, Inc. filed an 8-K on July 10, 2025, reporting other events and financial statements and exhibits. The filing does not contain specific financial figures or details about the 'other events' in the provided text.

Why It Matters

This filing indicates Jupiter Neurosciences is making a regulatory submission, but the specific details of the 'other events' are not yet disclosed in the provided text.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting events, and the provided text does not contain information suggesting significant risk.

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Jupiter Neurosciences?

The provided text of the 8-K filing does not specify the details of the 'Other Events'.

When was the report filed with the SEC?

The report was filed on July 10, 2025.

What is the principal executive office address for Jupiter Neurosciences?

The principal executive office is located at 1001 North US HWY 1, Suite 504, Jupiter, FL 33477.

What is the SIC code for Jupiter Neurosciences?

The Standard Industrial Classification (SIC) code is 2834 for Pharmaceutical Preparations.

Has Jupiter Neurosciences changed its name previously?

Yes, the company was formerly known as Jupiter Orphan Therapeutics, Inc., with a name change date of July 13, 2016.

From the Filing

0001641172-25-018619.txt : 20250710 0001641172-25-018619.hdr.sgml : 20250710 20250710170819 ACCESSION NUMBER: 0001641172-25-018619 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250709 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250710 DATE AS OF CHANGE: 20250710 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JUPITER NEUROSCIENCES, INC. CENTRAL INDEX KEY: 0001679628 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 474828381 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41265 FILM NUMBER: 251116939 BUSINESS ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 BUSINESS PHONE: (561) 406-6154 MAIL ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 FORMER COMPANY: FORMER CONFORMED NAME: Jupiter Orphan Therapeutics, Inc. DATE OF NAME CHANGE: 20160713 8-K 1 form8-k.htm 8-K false 0001679628 0001679628 2025-07-09 2025-07-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   July 9, 2025 Date of Report (Date of earliest event reported)   JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter)   Delaware   001-41265   47-4828381 (State or other jurisdiction   (Commission   (IRS Employer of incorporation)   File Number)   Identification No.)   1001 North US HWY 1 , Suite 504 , Jupiter , FL   33477 (Address of principal executive offices)   (Zip Code)   (561) 406-6154 Registrant’s telephone number, including area code   Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock   JUNS   Nasdaq Capital Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging Growth Company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 8.01 Other Events   As previously reported to the Securities Exchange Commission on a Form 8-K filed on March 25, 2025, Jupiter Neurosciences, Inc. (the “Company”) received a letter (the “Notice”) on March 21, 2025, from the Nasdaq Stock Market LLC (the “NASDAQ”) notifying the Company that it was not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)(2) for continued listing of its Common Stock on the NASDAQ.   Listing Rule 5550(a)(2) requires the registrant to maintain a minimum bid price of $

View on Read The Filing